Concepedia

Mark Morrow

MM

16

Publications

801

Citations

14

H-Index

1974

Active since

Affiliations

University of Colorado Denver(Current)

University of Colorado Cancer Center

National Cancer Institute

University of Colorado Anschutz Medical Campus

Ligand Pharmaceuticals (United Kingdom)

Mark Morrow is an author at University of Colorado Denver specializing in medicine, cancer research, and pharmacology.

Top concepts

Publications per year

1974–2010

16

Publications

16

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Seetharaman Hariharan, Daniel L. Gustafson, Scott N. Holden et al. · Annals of Oncology · 2007 · 122 citations

, , +11

Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

Bhuvaneswari Ramaswamy, Anthony Elias, Nicole Kelbick et al. · Clinical Cancer Research · 2006 · 121 citations · Full text

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

M. Basche, Daniel L. Gustafson, Scott N. Holden et al. · Clinical Cancer Research · 2006 · 95 citations

Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies

Eric K. Rowinsky, Rachel Humphrey, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2000 · 85 citations

Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models

Todd M. Pitts, Mark Morrow, Sara A. Kaufman et al. · Molecular Cancer Therapeutics · 2009 · 76 citations · Full text

, , +13

Rows per page

1–5 of 16